PR 39

Drug Profile

PR 39

Alternative Names: PR 26

Latest Information Update: 26 Jun 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Anti-ischaemics; Antibacterials; Peptide antibiotics; Peptides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections; Mycobacterial infections

Most Recent Events

  • 04 Sep 2001 An in vitro study has been added to the Bacterial Infections antimicrobial activity section
  • 26 Jul 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)
  • 04 May 2001 Preclinical development for Mycobacterial infections in Sweden (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top